(1957 Sing), GenBank AAA64366) and corresponding NA proteins and monoclonal antibodies CR6261 and F10 (S1,S2) were synthesized using human preferred codons as described (S3) by GeneArt (Regensburg, Germany) and cloned into a CMV/R expression vector for efficient expression in mammalian cells (S3) . The stem mutations were introduced using the QuikChange Site-Directed Mutagenesis kit (Agilent Technologies).
Production of pseudotyped lentiviral vectors and recombinant adenovirus 5.
The recombinant lentiviral vectors expressing a luciferase reporter gene were produced as previously described (S4) . For the production of H1N1 and H3N2 pseudovirus, a human type II transmembrane serine protease TMPRSS2 gene was included in transfection for the proteolytic activation of HA (S5) . Two replication-defective rAd serotype 5 vectors expressing 1999 NC or 1934 PR8 HA genes were produced as previously described (S6) .
Protein expression and purification. Plasmids expressing secreted wild-type or stem mutant 1999 NC HA were expressed in the human embryonic kidney cell line 293F.
The stem mutant has an Ile545Asn and a Gly547Thr (H3 numbering) change to introduce an N-linked glycosylation site into helix A in the middle of the stem. The addition of a glycan at this site is unlikely to block regions beyond the stem as it would have to stretch more than 40 Å to block any of the head region of HA (using the PR8/34 HA structure as a reference (PDB entry 1RU7). A complex N-linked glycosylation without terminal sialic acid was modeled to this site with the GlyProt Server (S7). The longest dimensions in this modeled glycosylation are only 32 Å. Even this distance would not be likely for antibody blocking given the uneven surface of the HA protein, the presence of several other nearby glycosylations and the fact that glycans generally project out from the protein surface rather than following the protein contour. Both WT and ∆Stem HAs Monoclonal antibodies CR6261 and F10, as well as the wild type and mutant stem trimer plasmid expression vectors, were transfected into the human embryonic kidney cell line 293F using 293fectin (Invitrogen) according to the manufacturer's instructions.
293F cells were cultured in Freestyle 293 Expression Medium (Invitrogen) and 3 supernatant was collected 72-96 hrs post-transfection and cleared by centrifugation and filtration. HA proteins were purified as previously described (S9) . Expression of HA proteins was confirmed by Western blotting using an anti-His tag antibody (Qiagen).
Antibodies were purified using a Protein G affinity column (GE Healthcare).
Neutralization,protein competition and cell absorption assays. The pseudotype neutralization assay has been widely accepted for defining the specificity of neutralizing antibodies targeting influenza HAs (S3,S4,S10). The increased sensitivity of the pseudotype neutralization assay makes it a useful tool to assess the neutralization induced by antibodies targeting the conserved stem region of HA which the MN assay often fails to pick up (S11). Moreover, because the HAI assay relies on antibodies that recognize the HA head, anti-stem antibodies cannot be detected using the HAI assay.
HA NA-pseudotyped lentiviral vectors encoding luciferase were first titrated by serial dilution. Similar amounts of virus (p24 ≈ 6.25 ng/ml) were then incubated with indicated amounts of mouse antisera for 20 minutes at room temperature and added to 293A cells (10,000 cells/well in a 96-well plate) (50 μl/well, in triplicate). Plates were then washed and replaced with fresh media 2 hours later, and luciferase activity was measured after 24 hours. For the protein competition assay, mouse or ferret antisera were pre-absorbed with HIV env (control), wild-type or stem mutant 1999 NC HA trimers (40 µg/ml) for 30 min and the pre-absorbed antisera were then used to measure neutralization activity against the indicated pseudoviruses. Cell absorptions of ferret or monkey sera were performed as previously described (S10). Monkey sera pre-absorbed with cells expressing wild-type or stem mutant 1999 NC HA were then used to perform ELISA assays on plates coated with 1999 NC, 1986 Sing or 2007 Bris HA trimers. For CR6261 antibody competition, ELISA plates coated with 1999 NC or 1986 Sing HA trimers were incubated with CR6261 (10 µg/ml) before the addition of ferret sera pre-absorbed with cells expressing the stem mutant 1999 NC HA. Ferret antibodies were detected with an anti-ferret secondary antibody (Rockland). The ELISA assay was performed as described previously (S12). TCID 50 of the PR8/34 stock used for the mouse challenge experiment was 10 7.5 /ml. Sera were treated with receptor-destroying enzyme (RDE) by diluting one part serum with three parts enzyme and incubated overnight in a 37°C water bath. The enzyme was inactivated by 30 min incubation at 56°C followed by addition of six parts PBS for a final dilution of 1/10. HAI assays were performed in V-bottom 96-well plates using four hemagglutinating units (HAU) of virus and 0.5% turkey RBC.
Microneutralization (MN) assay. Neutralizing antibody activity was analyzed
in an MN assay based on the methods of the WHO Global Influenza Program (S13). Sera were treated with RDE by diluting one part serum with three parts enzyme and incubated overnight in a 37°C water bath and heat-inactivated as described for the HAI assay. GA) and has a titer of 10 6.5 EID/ml. The virus stock was inoculated intranasally into ferrets, which had been anesthetized with Ketamine/Xylazine, in a volume of 0.5 ml per nostril. The ferrets were observed for clinical signs twice daily and weight and temperature measurements recorded daily by technicians blind to the treatment groups.
Nasal washes were obtained on days 1, 2, 3, 5, 7, 9, and 14 post challenge and infectious viral titers determined by a TCID 50 or EID 50 assay. For TCID 50 , 10-fold dilutions of nasal wash were added to a 96-well round-bottomed tissue culture plate. As a positive control, 10-fold dilutions of the challenge virus were included in each experiment.
MDCK cells were then added to all wells and the plates were incubated overnight at 37°C, 5% CO 2 . The medium was discarded and replaced with TPCK-trypsin-containing medium. The plates were incubated for another 4 days. At this time, 50 µl from each well was transferred to a 96-well V-bottomed microtiter plate, 0.5% turkey RBC were 7 added to all wells and the presence of virus detected by hemagglutination as a read-out.
The infectious titer was calculated by the method of Reed and Muench (S15). For EID 50 , virus titers in clarified nasal washes were determined in eggs from an initial dilution of 1:10 in PBS and expressed as EID 50 /ml. The limit of virus detection was 10 1.5 EID 50 /ml.
Flow Cytometric Analysis of Intracellular Cytokines. CD4 + and CD8 + T-cell responses were evaluated using intracellular cytokine staining for IFN-γ and TNF-α as described (S16) with peptide pools (15 mers overlapping by 11 aa, 2.5 µg/ml each) covering 1999 NC HA proteins. Cells were then fixed, permeabilized, and stained by using rat monoclonal anti-mouse CD3, CD4, CD8, IFN-γ, and TNF-α (BD-PharMingen).
The IFN-γ and TNF-α positive cells in the CD4 + and CD8 + cell populations were analyzed with the program FlowJo (Tree Star).
Surface plasmon resonance. Biacore 3000 (GE Healthcare) was used in all experiments. Antibodies were coupled to Biacore CM5 chips using standard amine coupling. HA or control proteins (500 nM) were flowed over the chip at a flow rate of 30 µL/min for either 5 min or 8 min, followed by injection of Biacore HBS-EP buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3mM EDTA, 0.005 % surfactant P-20) for 5 min. Antibodies were coupled to Biacore CM5 chips to final densities ranging from ~700 to 3000 response units (RU). The WT HA protein bound to all four antibodies, while ∆Stem lacked observed binding to C179, F10, and CR6261. The HIV Env protein failed to bind to any of the antibodies and served as a negative control.
